Abstract

Synovial sarcoma (SS) is a fusion-driven subtype of sarcoma that is a more chemo-sensitive subtype of soft tissue sarcoma. While chemotherapy options are currently standard of care, our fundamental understanding of the biology of SS is driving new therapies. We will review the current standard of care, as well as the current therapies showing promise in a clinical trial. It is our hope that by encouraging participation in clinical trials, the fundamental therapies available for SS will change the current treatment paradigm.

Original languageEnglish
Pages (from-to)229-239
Number of pages11
JournalCurrent treatment options in oncology
Volume24
Issue number3
DOIs
StatePublished - Mar 2023

Fingerprint

Dive into the research topics of 'Relapsed Synovial Sarcoma: Treatment Options'. Together they form a unique fingerprint.

Cite this